ALLMedicine™ Gastrointestinal Hemorrhage Center
Research & Reviews 357 results
https://doi.org/10.1007/s10620-022-07514-8 10.14309/ajg.0000000000001245 10.1053/j.gastro.2018.08.063 10.1111/j.1365-2036.2005.02485.x 10.1148/rg.2018170138 10.1038/ajg.2016.41 10.1038/ajg.2015.246 10.1016/S0016-5107(95)70037-4 10.1007/s00330-009-1510-7 10.1186/s13017-016-0112-3 10.1001/jamasurg.2015.97 10.1097/MCG.0b013e31823337ee 10.1007/s00330-012-2721-x 10.1016/j.ejrad.2017.05.020 10.3748/wjg.v16.i31.3957 10.3348/kjr.2015.16.3.541 10.14309/00000434-201710001-00591 10.1148/radiol.2283020756 10.1007/s00330-008-0907-z 10.1016/j.ajem.2020.01.015 10.1007/s10140-016-1391-4 10.3174/ajnr.A6408 10.1016/j.clinimag.2017.02.006 10.1007/s00270-014-0928-8 10.1503/cjs.005611 10.1186/s12876-020-01570-y
Digestive Diseases and Sciences; Spiritos Z, Horton A et. al.
May 14th, 2022 - Acute gastrointestinal (GI) bleeding is one of the leading causes of emergency department visits and hospital admissions. CT angiography (CTA) has had an expanding role in the evaluation of acute GI bleeding because it is rapidly performed, widely...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087945
BMC Gastroenterology; Ye N, Bao X et. al.
May 10th, 2022 - Primary duodenal cancer (PDC) is rare, especially signet-ring cell carcinoma (SRCC) of the duodenal bulb, and it is commonly misdiagnosed as an ulceration. Here, we report a rare case of SRCC of the duodenal bulb presenting with gastrointestinal h...
https://doi.org/10.1097/JCP.0000000000001546
Journal of Clinical Psychopharmacology; Huang H, Zhang P et. al.
May 1st, 2022 - Gastrointestinal Hemorrhage After Antidepressant Drug Use: A Case Report.|2022|Huang H,Zhang P,Wu L,Lai J,Hu S,|adverse effects,chemically induced,complications,
https://clinicaltrials.gov/ct2/show/NCT04174989
Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...
https://doi.org/10.17219/acem/147464
Advances in Clinical and Experimental Medicine : Official... Rogalski P, Zaborowska M et. al.
Apr 20th, 2022 - Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and very high short-term mortality. To assess the incidence and factors predisposing to ACLF in patie...
Guidelines 1 results
https://doi.org/10.1055/s-0034-1393172
Endoscopy Gralnek IM, Dumonceau JM et. al.
Sep 30th, 2015 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH). Main Recommendations MR1. ESGE recommends im...
Drugs 58 results see all →
Clinicaltrials.gov 13 results
https://clinicaltrials.gov/ct2/show/NCT04174989
Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...
https://clinicaltrials.gov/ct2/show/NCT01717599
May 4th, 2021 - The study described in this report will be approved by the ethics committee of Yonsei University School of Medicine, Seoul, Korea. Between July 2012 and February 2013, 380 patients fulfilled the inclusion criteria, 380 of whom were included in the...
https://clinicaltrials.gov/ct2/show/NCT04184934
Jul 21st, 2020 - Specific aims of this study : To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis. To investigate the ability of novel biomarkers to predict the de...
https://clinicaltrials.gov/ct2/show/NCT03812705
Apr 20th, 2020 - The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD). Inclusion criteria: Age>= 14 yrs ≤60 yrs. Di...
https://clinicaltrials.gov/ct2/show/NCT04264260
Feb 11th, 2020 - Study procedures Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the rig...
News 71 results
https://www.onclive.com/view/gynecologic-oncologists-continue-to-pursue-novel-agents-immunotherapy-in-ovarian-cancer
Oct 6th, 2021 - The ovarian cancer armamentarium continues to evolve with novel agents, such as antibody-drug conjugates (ADCs) and immunotherapy, even with clinical trial findings showing mixed, yet intriguing, results with these classes of agents. In a prese...
https://www.onclive.com/view/real-world-data-suggest-unmet-need-for-effective-post-btk-inhibitor-options-in-mcl
Aug 18th, 2021 - For patients with mantle cell lymphoma (MCL) who have progressed after treatment with a BTK inhibitor such as ibrutinib (Imbruvica), there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal ou...
https://www.onclive.com/view/glofitamab-demonstrates-durable-responses-in-relapsed-refractory-b-cell-lymphoma
Apr 21st, 2021 - The novel T-cell–engaging bispecific antibody glofitamab (RO7082859) demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive...
https://www.onclive.com/view/updated-cabozantinib-data-includes-6-patient-deaths
Dec 20th, 2020 - Nicholas J. Vogelzang, MD Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO’s annual meeting. The fatalities had not been reported with the c...
https://www.onclive.com/view/atezolizumab-plus-vemurafenib-cobimetinib-impresses-in-braf-v600-melanoma
Dec 20th, 2020 - Grant A. McArthur, MBBS, PhD Treatment with atezolizumab (Tecentriq) in combination with vemurafenib (Zelboraf) and cobimetinib (Cotellic) was found to significantly improve progression-free survival (PFS) and produce durable responses versus vem...